Table 5 Effect of montelukast in different subjects’ subgroups
From: Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast
Baseline | 4 weeks | 8 weeks | |
|---|---|---|---|
ACT nonatopic (montelukast) | 22.2 ± 1.8 | 20.8 ± 4.6 | 23.6 ± 2.1 |
ACT nonatopic (placebo) | 23.8 ± 0.8 | 20.4 ± 6 | |
ACT ≤ 21 (montelukast) | 20.2 ± 1.8 | 22 ± 2 | 21.2 ± 6.4 |
ACT ≤ 21 (placebo) | 21.8 ± 3.3 | 19.8 ± 7.1 | |
ACT IgE > 200 IU/ml (montelukast) | 22.6 ± 2.7 | 23.5 ± 1.7 | 22 ± 5 |
ACT IgE > 200 IU/ml (placebo) | 23 ± 3 | 22 ± 5.4 | |
FEV1% < 60% (montelukast) | 54.5 ± 5.4 | 50.8 ± 9.5 | 52.2 ± 6.3 |
FEV1% < 60% (placebo) | 50.3 ± 4.9 | 51.8 ± 6.4 | |
Eosinophils ≥ 0.6 K/μL (montelukast) | 0.83 ± 0.22 | 0.54 ± 0.11 | |
Eosinophils ≥ 0.6 K/μL (placebo) | 1.22 ± 0.5 |